{"id":6263,"date":"2024-08-31T09:00:42","date_gmt":"2024-08-31T08:00:42","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?p=6263"},"modified":"2025-04-28T22:45:25","modified_gmt":"2025-04-28T20:45:25","slug":"interactive-development-program","status":"publish","type":"post","link":"https:\/\/beonemedaffairs.com\/us\/6263\/interactive-development-program\/","title":{"rendered":"Interactive Development Program"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":17,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"editor_notices":[],"footnotes":""},"categories":[4],"post-tag":[],"specialisation":[],"class_list":["post-6263","post","type-post","status-publish","format-standard","hentry","category-reading"],"acf":{"visible_for_guests":false,"title":"Interactive BeiGene Pipeline Tool","card_title":"","title_for_guests":"","summary":"Browse BeiGene\u2019s interactive pipeline of oral small molecules and monoclonal antibodies to treat cancer.","card_summary":"","summary_for_guests":"","show_popup_window_to_guests":true,"blur_thumbnail_for_guests":false,"text_app":"","text":"","content-type":4,"download_file_reading":null,"display_file_reading":null,"download_file_slidekit":null,"display_file_slidekit":null,"3qsdn":"","motionposter":false,"webcast":"","videolange":null,"fliphtml_link":"https:\/\/health-ecomm.com\/beigene\/webgl\/Portfolio_NoMenu.html","authors":"","specialisation":[],"tags":[190,46],"visible_tags":[190,46],"post_image":6449,"post_image_for_guests":"","related_posts":[{"id":6379,"title":"NMA: Comparison of efficacy between BTKis in high-risk R\/R CLL","title_guest":"","summary":"Network Meta-Analysis (NMA) methodology is explained in this video hosted by\u00a0Dr Mazyar Shadman, MD, MPH, Associate Professor at Fred Hutch Cancer Centre and the University of Washington School of Medicine. This video covers how to connect three or more trials using common comparators to estimate relative efficacy outcomes. Highlights include the practical use of NMA, differences between MAIC and NMA, and a worked through example using the ASCEND, ALPINE, and ELEVATE-RR trials in relapsed\/refractory CLL (R\/R CLL). This video is aimed at those interested in advanced health research methods.","summary_guest":"","content-type":5,"post_image":6380,"blur_thumbnail_guest":false,"post_image_guest":false,"videolange":"00:15:06","url":"https:\/\/beonemedaffairs.com\/us\/6379\/beigene-animation-nma\/","date":"2024-06-05T08:07:54","date_gmt":"2024-06-05T06:07:54"},{"id":6359,"title":"MAIC: Efficacy of Zanubrutinib versus Acalabrutinib in R\/R CLL","title_guest":"","summary":"Join Dr. Mazyar Shadman, MD, MPH, Associate Professor at Fred Hutch Cancer Centre and the University of Washington School of Medicine, in our educational video on Matching Adjusted Indirect Comparison (MAIC) methodology. In this video, we explore the use of MAIC for comparing the efficacy of zanubrutinib vs. acalabrutinib, using patient level data from the ALPINE trial and published data from the ASCEND trial, respectively. Our results emphasize a few methodological aspects of MAICs, such as the parameters matched in the analysis, the effective sample size, importance of sensitivity analysis, data cut-offs used and the impact of COVID-19 where relevant. Perfect for those keen on advanced healthcare research.","summary_guest":"","content-type":5,"post_image":6387,"blur_thumbnail_guest":false,"post_image_guest":false,"videolange":"00:14:39","url":"https:\/\/beonemedaffairs.com\/us\/6359\/avt-303-beigene-animation-maic\/","date":"2024-05-30T09:00:54","date_gmt":"2024-05-30T07:00:54"},{"id":6353,"title":"Zanubrutinib MoA","title_guest":"","summary":"Zanubrutinib is a next-generation Bruton\u2019s tyrosine kinase inhibitor (BTKi) designed for selectivity, potency, and bioavailability. Watch the mode of action (MoA) video to learn more.","summary_guest":"","content-type":5,"post_image":7226,"blur_thumbnail_guest":false,"post_image_guest":false,"videolange":"22:02:26","url":"https:\/\/beonemedaffairs.com\/us\/6353\/zanubrutinib-moa-video\/","date":"2024-05-29T09:00:54","date_gmt":"2024-05-29T07:00:54"},{"id":936,"title":"Tislelizumab MoA","title_guest":"","summary":"Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind and inhibit PD\u20111. Watch the mode of action (MoA) video to learn more.","summary_guest":"","content-type":5,"post_image":7227,"blur_thumbnail_guest":true,"post_image_guest":false,"videolange":"22:04:00","url":"https:\/\/beonemedaffairs.com\/us\/936\/tislelizumab-moa-video\/","date":"2024-05-29T09:00:52","date_gmt":"2024-05-29T07:00:52"}]},"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/posts\/6263","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/comments?post=6263"}],"version-history":[{"count":5,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/posts\/6263\/revisions"}],"predecessor-version":[{"id":7181,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/posts\/6263\/revisions\/7181"}],"acf:term":[{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/46"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/190"},{"embeddable":true,"taxonomy":"category","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/categories\/4"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6263"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/categories?post=6263"},{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6263"},{"taxonomy":"specialisation","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/specialisation?post=6263"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}